Development of new tools for surveillance of chlamydial infections in sheep. This project aims to improve health in sheep and reduce on-farm losses for Australian producers, by developing new serological tests for chlamydial infections in sheep. These infections can result in significant on-farm losses and loss of trade in the live export industry. Currently, surveillance of chlamydial infections is hindered by outdated serological tools that are unreliable and difficult to interpret. The ser ....Development of new tools for surveillance of chlamydial infections in sheep. This project aims to improve health in sheep and reduce on-farm losses for Australian producers, by developing new serological tests for chlamydial infections in sheep. These infections can result in significant on-farm losses and loss of trade in the live export industry. Currently, surveillance of chlamydial infections is hindered by outdated serological tools that are unreliable and difficult to interpret. The serological tests to be developed aim to be species-specific tests to detect the most important chlamydial sheep pathogens. This in turn endeavours to improve domestic surveillance, reducing on-farm losses and costs, and improve market opportunities for Australian sheep exporters as well as informing veterinary populations on best practice treatment.Read moreRead less
Industrial Transformation Research Hubs - Grant ID: IH220100017
Funder
Australian Research Council
Funding Amount
$4,808,669.00
Summary
ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals. Radiopharmaceuticals are emerging as next generation medical technologies for addressing complex health challenges, and their manufacture offers significant economic benefit to Australia. The ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals (AMTAR) aims to establish a manufacturing platform for new medical technologies combining innovations in biotechnology and pharmaceutical science. The progra ....ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals. Radiopharmaceuticals are emerging as next generation medical technologies for addressing complex health challenges, and their manufacture offers significant economic benefit to Australia. The ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals (AMTAR) aims to establish a manufacturing platform for new medical technologies combining innovations in biotechnology and pharmaceutical science. The program addresses industry-led challenges for translation of biologics as molecular radiopharmaceuticals, building capacity in biomanufacturing, radiobiology and radiochemistry. The program establishes a dedicated manufacturing pipeline, future-proofing production and securing supply chain of next generation medical technologies.Read moreRead less
ARC Centre of Excellence in Quantum Biotechnology. ARC Centre of Excellence in Quantum Biotechnology. The ARC Centre of Excellence in Quantum Biotechnology aims to develop paradigm-shifting quantum technologies to observe biological processes and transform our understanding of life. It seeks to create technologies that go far beyond what is possible today, from portable brain imagers to super-fast single protein sensors, and to use them to unravel key problems including how enzymes catalyse reac ....ARC Centre of Excellence in Quantum Biotechnology. ARC Centre of Excellence in Quantum Biotechnology. The ARC Centre of Excellence in Quantum Biotechnology aims to develop paradigm-shifting quantum technologies to observe biological processes and transform our understanding of life. It seeks to create technologies that go far beyond what is possible today, from portable brain imagers to super-fast single protein sensors, and to use them to unravel key problems including how enzymes catalyse reactions and how higher brain function emerges from networks of neurons. By building a diverse, multidisciplinary, and industry-engaged ecosystem, the Centre means to develop our future leaders at the interface of quantum science and biology and drive Australian innovation across manufacturing, energy, agriculture, health, and national security.Read moreRead less
Pharmacology Of Potential Anti-Tumour Agents: Iron Chelators Of The BpT Class
Funder
National Health and Medical Research Council
Funding Amount
$585,455.00
Summary
Pharmacology of Potential Anti-Tumour Agents: Iron Chelators of the BpT Class Cancer cells have a high iron requirement for DNA synthesis and many clinical trials showed Fe chelators are effective anti-cancer drugs. Their potential to act as anti-tumour agents has been confirmed by the entrance of Triapine into widespread NCI clinical trials. In this NHMRC Renewal, we will perform pharmacological and preclinical studies to promote the development of BpT chelators as novel anti-tumour agents.
ARC Centre of Excellence in Convergent Bio-Nano Science and Technology. The CoE in Convergent Bio-Nano Science &Technology comprises a multi-disciplinary team focused on research aiming to understand and control the interface of materials with biological systems. The Centre will exploit knowledge of the bio-nano interface to design materials that transport and deliver vaccines, drugs and gene therapy agents, and to design new diagnostic agents and devices. Nanomedicines are on the cusp of revol ....ARC Centre of Excellence in Convergent Bio-Nano Science and Technology. The CoE in Convergent Bio-Nano Science &Technology comprises a multi-disciplinary team focused on research aiming to understand and control the interface of materials with biological systems. The Centre will exploit knowledge of the bio-nano interface to design materials that transport and deliver vaccines, drugs and gene therapy agents, and to design new diagnostic agents and devices. Nanomedicines are on the cusp of revolutionizing diagnosis and therapy in many diseases. The CoE will be the focus of bio-nano research activity in Australia, uniting universities, research agencies, institutes and companies. The expected outcomes are better diagnostic and therapeutic tools designed via an enhanced understanding of the bio-nano-interface.Read moreRead less
Linkage Infrastructure, Equipment And Facilities - Grant ID: LE0989759
Funder
Australian Research Council
Funding Amount
$360,000.00
Summary
Australian Access to and Operation of Advanced Synchrotron Radiation Facilities at the Photon Factory. The primary national benefit of this application will be continued access by peer review for Australian scientists to the advanced synchrotron-radiation capabilities of the Australian National Beamline Facility and other complementary beamlines at the Photon Factory, Japan. This proposal is consistent with the National Research Priorities of An Environmentally Sustainable Australia, Promoting a ....Australian Access to and Operation of Advanced Synchrotron Radiation Facilities at the Photon Factory. The primary national benefit of this application will be continued access by peer review for Australian scientists to the advanced synchrotron-radiation capabilities of the Australian National Beamline Facility and other complementary beamlines at the Photon Factory, Japan. This proposal is consistent with the National Research Priorities of An Environmentally Sustainable Australia, Promoting and Maintaining Good Health and Frontier Technologies for Building and Transforming Australian Industries and will generate science to support and stimulate domestic industry, enhance the domestic knowledge base and international research profile, train students and future synchrotron scientists and foster domestic and international collaborations.Read moreRead less
Discovery Early Career Researcher Award - Grant ID: DE120101550
Funder
Australian Research Council
Funding Amount
$375,000.00
Summary
Understanding multidrug resistance: identifying the molecular basis of substrate and inhibitor transport by P-glycoprotein. Chemotherapy resistance causes 90 per cent of cancer deaths and is commonly triggered by the increased activity of P-glycoprotein, which controls the cellular clearance of drugs. This project will determine how P-glycoprotein recognises and transports drugs, essential knowledge for the design of anticancer agents that can stop chemotherapy resistance.